Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

Pfizer has made a new and improved bid to acquire AstraZeneca with an offer worth £69.3 billion pounds ($116.6 billion) or £55 a share – and says this is its best and final offer for the firm.

Pfizer has officially declared its £69 billion bid to acquire AstraZeneca dead - but hasn't ruled out another attempt in a few months' time. The US company has been in open pursuit of AstraZeneca ...

Pfizer’s patents for Vyndaqel/Vyndamax are set to expire ... Recent partnerships have secured Bayer's rights to acoramidis in Europe and AstraZeneca's rights in Japan, while BridgeBio focuses on the ...

AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial.

The company is already working with multiple large hospitals in the U.S. and Israel, as well as drug companies, including AstraZeneca and Pfizer. Promise Bio is now emerging from stealth with a ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

This article summarizes key developments in the health sector including a lawsuit blocking UnitedHealth's purchase of ...

Disease progression in metastatic breast cancer is a challenge that no single entity can solve alone. Breakthroughs in ...